Science Advances: The most painful trigeminal neuralgia in humans, the therapeutic target is here

Trigeminal neuralgia is the most common cranial nerve disease, characterized by recurrent paroxysmal severe pain in the distribution area of ​​the trigeminal nerve on one side of the fa.

To date, the pathophysiological molecular mechanisms of trigeminal neuralgia remain poorly understood, leading to a severe lack of therapeutic dru.

On August 3, 2022, researchers at Johns Hopkins University published a research paper titled: Identification of the NRF2 transcriptional network as a therapeutic target for trigeminal neuropathic pain in Science Advanc.

This study shows that reactive oxygen species (ROS) accumulate in the cerebrospinal fluid of patients with trigeminal neuralgia, and they directly activate the pain ion channel TRPA1, which further identifies the NRF2 transcriptional network as a potential therapeutic target for trigeminal neuralg.

In this latest study, the research team found evidence that increased oxidative stress contributes to trigeminal neuropathic pa.

The research team further found that inhibiting TRPA1 pharmacologically or at the genetic level reduced pa.

In this study, the research team found that activating the NRF2 antioxidant transcriptional network had as potent analgesic effects as direct inhibition of TRPA1, while also reversing underlying oxidative stre.

Using a transcriptome-guided drug discovery strategy, the research team identified two NRF2 network regulators, Exemestane and JQ- Exemestane has been approved by the FDA for the treatment of estrogen receptor-positive breast canc.

Overall, this study uses a combination of clinical, molecular and computational approaches to identify the NRF2 transcriptional network as a potential therapeutic target for trigeminal neuralg.

Original source:

CHIRAG VASAVDA, et .